John Coutsouvelis,* Carmela E Corallo†
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Clark TE, Edom N, Larson J, Lindsey LJ. Thalomid (thalidomide) capsules. A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Safety 2001; 24: 87-117.
- 2. Kaur A, Yu SS, Lee AJ, Chiao TB. Thalidomide-induced sinus bradycardia. Ann Pharmacother 2003; 37: 1040-1043.
- 3. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000; 75: 897-901.
- 4. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779.
- 5. Singhal S, Mehta J. Thalidomide in cancer. Biomed Pharmacother 2002; 56: 4-12.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Associate Professor Joseph McKendrick, Director of Oncology, Box Hill Hospital; Dr Michael Tong, Haematologist, Box Hill Hospital; and Oncology Day Centre staff, Box Hill Hospital.